Re-routing the GPS directing immunotherapy in endometrial cancer.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

MMR status alone is insufficient to guide the use of PD-(L)1 monotherapy in endometrial cancer patients. Additional biomarkers, including TMB and CPS score may help to identify patients with pMMR tumors with a high probability of benefit from PD-(L)1 monotherapy, and those with dMMR tumors who might require combination strategies.

Keyphrases

endometrial cancer
combination therapy
open label
randomized controlled trial
study protocol